Patients without COPD who took beta-blockers presented with younger age, higher BMI, lower prevalence of NYHA classification at discharge ≥III and cachexia, higher albumin, and higher prevalence of RAS inhibitors compared to those who did not. This evidence concerns the gene ALB and Cachexia.